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Tumor cells have an altered metabolic phenotype
characterized by increased glycolysis and dimin-
ished oxidative phosphorylation. Despite the sus-
pected importance of glycolysis in tumorigenesis,
the temporal relationship between oncogene sig-
naling, in vivo tumor formation, and glycolytic
pathway activity is poorly understood. Moreover,
how glycolytic pathways are altered as tumors
regress remains unknown. Here, we use a switchable
model of Myc-driven liver cancer, along with hyper-
polarized 13C-pyruvatemagnetic resonance spectro-
scopic imaging (MRSI) to visualize glycolysis in de
novo tumor formation and regression. LDHA abun-
dance and activity in tumors is tightly correlated
to in vivo pyruvate conversion to lactate and is rapidly
inhibited as tumorsbegin to regress, as are numerous
glycolysis pathway genes. Conversion of pyruvate to
alanine predominates in precancerous tissues prior
to observable morphologic or histological changes.
These results demonstrate that metabolic changes
precede tumor formation and regression and are
directly linked to the activity of a single oncogene.
INTRODUCTION
Cellular transformation has been correlated with increased
aerobic glycolysis and diminished oxidative phosphorylation
(Warburg Effect) (Christofk et al., 2008; Dang and Semenza,
1999; Vander Heiden et al., 2009; Warburg, 1956). Increased
glycolysis may contribute both to energy production and the
generation of metabolic intermediates that sustain anabolic
processes required for rapid tumor growth (Vander Heiden
et al., 2009). Lactate dehydrogenase A (Ldha) is a key regulator
of glycolysis, and its inhibition can attenuate the growth of
transplanted tumor cells (Fantin et al., 2006; Le et al., 2010).We sought to determine whether glycolytic changes could be
detected prior to other pathological alterations. To visualize the
temporal connection between oncogene signaling and glycol-
ysis in de novo tumor formation, we used a switchable trans-
genic model of Myc-driven liver cancer (Goga et al., 2007; Sha-
chaf et al., 2004). Double-transgenic LAP-tTA (LT2)3 TRE-MYC
(MYC) mice (hereafter called LT2/MYC) express the Myc
oncogene specifically in hepatocytes in a doxycycline-regulated
manner and give rise to tumors that have features of human
hepatocellular carcinoma and hepatoblastoma (Cairo et al.,
2008; Shachaf et al., 2004). This model allows us to examine
in vivo glycolytic changes at different stages of liver tumor forma-
tion as well as the consequence of acutely inhibiting oncogene
signaling in established tumors. Hyperpolarized 13C MRSI, an
emerging metabolic imaging modality (Golman et al., 2006; Hu
et al., 2010), was used to visualize glycolysis at different stages
of de novo tumor formation and regression in LT2/MYC mice.
We show that hyperpolarized 13C MRSI can detect metabolic
changes during tumor formation as well as when tumors regress.
We find that pyruvate to lactate conversion increased as tumors
developed and was rapidly inhibited during regression.
Numerous glycolysis pathway genes showed a similar expres-
sion pattern. Interestingly, conversion of pyruvate to alanine
was predominant in very early stages of tumorigenesis, prior to
any observable morphologic or histological changes. Changes
in gene expression of glutamine and tricarboxylic acid (TCA)
cycle pathways was also altered indicating that global metabolic
changes occur as tumors form and regress. These results
demonstrate that metabolic changes precede tumor formation
and regression and are directly linked to the activity of a single
oncogene such asMyc. Our study further highlights the potential
of high alanine levels as an early biomarker for liver tumor
development.RESULTS
Doxycycline-Regulated MYC Expression Precedes Liver
Tumor Formation and Is Inhibited During Regression
We first sought to define the different stages of tumorigenesis
and regression. Control (LT2) mice and LT2/MYC mice keptCell Metabolism 14, 131–142, July 6, 2011 ª2011 Elsevier Inc. 131
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Figure 1. Switchable MYC expression in Primary Liver Tumor Formation and Early Regression
(A) Gross tissues, corresponding histology andMYC staining at different stages of tumor formation and early regression. No apparent histologic differences were
noted between primary tumors and early regression sections. MYC expression (indicated with arrowheads) is heterogeneous in pretumor tissue, is significantly
increased in tumors, and is absent after 72 hr of doxy treatment.
(B and C) Quantitative PCR (B) and western blots (C) show negligible MYC expression in early-stage pretumor liver compared to elevated expression in
established tumors. MYCmRNA and protein expression is switched off when doxy is administered for 3 days. The liver tumor marker, AFP is highly expressed in
tumor tissue and persists once MYC is switched off (C).
(D and E) Comparison of staining for the Ki67 proliferation marker (D) and TUNEL assay (E) of liver samples at different stages of tumor development and
regression.
(F) Graph depicting percentage of Ki67-positive cells.
(G) Graph depicting percentage of TUNEL-positive cells.
Error bars represent the standard error of the mean (SEM). *p < 0.004. N.S., not significant.
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Metabolic Changes Precede Tumorigenesiscontinuously on doxycycline (doxy) do not express the Myc
transgene and do not form tumors (Figures 1A–1C). When
doxycycline-containing food is withdrawn from LT2/MYC mice
for 4–5 weeks, theMyc transgene is modestly induced, but there
are no apparent phenotypic or histological changes to indicate
tumor formation (Figures 1A–1C). Prolonged removal of doxy
for 8–10 weeks results in the formation of discrete tumor
nodules, which have features of an aggressive malignancy.
LT2/MYC tumors are comprised of small basophilic cells, with
a high nuclear to cytoplasmic ratio, frequent mitotic figures indi-
cating high proliferation and occasional apoptotic cells (Fig-
ure 1A) (Goga et al., 2007; Shachaf et al., 2004). These tumor
nodules are also associated with 20-fold increased MYC
mRNA and protein expression compared to the pretumor liver
tissues (Figures 1B and 1C). Immunohistochemical staining for
MYC shows a heterogeneous upregulation in a small subset of
pretumor liver cells, but a much more dramatic and uniform
increased expression in tumor tissues (Figure 1A). This shows
that the Myc transgene is not uniformly activated in all cells of
the mouse liver. This resembles human tumor initiation and132 Cell Metabolism 14, 131–142, July 6, 2011 ª2011 Elsevier Inc.progression wherein activation of the driving oncogene may
occur in subsets of cells within a tissue.
Thismodel systemalso allows for inhibition ofMYCexpression
in primary tumors by addition of doxycycline to the mice’s diet.
Prolonged doxy administration can lead to complete regression
of Myc-driven liver tumors; however, this takes several weeks
(Shachaf et al., 2004) (data not shown). Since we sought to
examine the acute metabolic changes that occur once the
expression of a driving oncogene such as Myc is inhibited, we
treated mice with established tumors with doxy for only 72 hr.
We found that at this time point MYC expression is completely
inhibited (Figures 1A–1C); however, tumors phenotypically and
histologically appear nearly indistinguishable from primary
tumors (Figure 1A). At the early stage of tumor regression, we
found that there was no substantial change in apoptosis;
however, proliferation, asmeasuredbyKi-67 staining,was signif-
icantly diminished (Figures 1D–1G). These results indicate that
acute inhibition of MYC precedes gross tumor regression.
In addition to following changes in tissue histology, we sought
an independent marker of liver tumorigenesis that would allow
Figure 2. Changes in Gene Expression
during Myc-Driven Tumor Development
and Regression
GSEA analysis of 120 previously reported MYC-
regulated genes. Shown are subsets of the 120
genes that are most abundantly enriched or
downregulated when comparing normal liver
versus tumor tissues (A) or tumor tissues versus
early regression samples (B). See also Table S1.
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Metabolic Changes Precede Tumorigenesisus to examine different liver tumor stages in our models. Alpha-
fetoprotein (AFP) is a well-established clinical biomarker of
human HCC and hepatoblastoma, but it is not detectable in
normal liver. We therefore examined AFP expression in the
different stages of liver tumor formation. We found that AFP
is not detectable in nontumor LT2 tissues and is negligible in
the pretumor LT2/MYC tissues (Figure 1C). In contrast, primary
liver tumors demonstrate abundant AFP expression (Figure 1C).
After 72 hr of doxy treatment, despite the complete inhibition
of MYC expression, there is no discernible decrease in AFP
expression (Figures 1B and 1C). Thus, liver tissue histology
and AFP expression indicate that MYC expression precedes
tumor formation and liver tumor regression follows MYC
inhibition.Cell Metabolism 14, 131To better understand the gene expres-
sion changes that underlie Myc-driven
tumor formation and regression, we
performed messenger RNA (mRNA)
profiling of liver samples at each stage.
We selected a subset of 120 genes
whose expression is altered in a MYC-
dependent manner to determine if gene
expression is changed in primary liver
tumors as a consequence of inhibiting
MYC (Table S1 available online). Most of
these genes were previously identified in
studies examining gene expression
changes in tissue culture models. Genes
in this test set are associated with diverse
molecular functions including cell cycle,
apoptosis, DNA damage, chromatin
remodeling, and metabolic pathways
such as glycolysis and amino acid meta-
bolic pathways (annotated at http://
www.myc-cancer-gene.org/). We per-
formed gene set enrichment analysis
(GSEA), a computational method that
determines whether there are concordant
differences between two groups based
on enrichment of the genes in one group
compared with the other (Subramanian
et al., 2005). This analysis confirmed
that MYC target genes were significantly
enriched in Myc tumors compared to
normal livers (Figure 2A, p < 0.0001). Like-
wise, there was an enrichment of the
MYC target genes in primary tumors
compared to early regression samples(Figure 2B, p < 0.0001). Thus,Myc-driven tumorigenesis causes
widespread changes in gene expression as primary tumors form
and as they begin to regress.
Hyperpolarized 13C-Pyruvate Flux into Other
Metabolites at Different Stages of Myc-Driven Liver
Tumor Development and Regression
We next examined whether dynamic changes in metabolic
processes occur in vivo and whether any metabolic changes
precede overt tumorigenesis using the switchable Myc liver
tumor model. We evaluated in vivo glycolysis at different stages
of liver tumor formation and regression by examining the
dynamic flux of pyruvate, a key product of glycolysis, into
other metabolites. Hyperpolarized technology utilizing dynamic–142, July 6, 2011 ª2011 Elsevier Inc. 133
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Metabolic Changes Precede Tumorigenesisnuclear polarization (DNP) (Ardenkjaer-Larsen et al., 2003) can
be used with the substrate [1-13C] pyruvate to specifically
monitor LDH-catalyzed pyruvate to lactate flux in vivo. Hyperpo-
larized MRSI overcomes sensitivity limitations in traditional
carbonMRSI caused by a low gyromagnetic ratio and low natural
abundance of theMR detectable 13C isotope. With a hyperpolar-
ized approach, enhancement of sensitivity on the order of
50,000-fold can be achieved for in vivo metabolic imaging.
[1-13C] pyruvate, which is converted to [1-13C] lactate, [1-13C]
alanine, and [1-13C] bicarbonate in vivo (Figure 3A), has been
recently used to visualize tumor tissues in a lymphoma transplant
model as well as in a transgenic prostate cancer model (Albers
et al., 2008; Day et al., 2007). In these prior instances, increased
pyruvate conversion to lactate was observed in tumor versus
adjacent tissue, however, in neither of these prior studies was
the temporal association between oncogene signaling, LDH
activity and in vivo glycolysis examined.
In the cell, pyruvate may be converted to acetyl co-A, lactate
or via transamination, into alanine. Conversion of pyruvate into
lactate or alanine (Figure 3A) can be visualized by MRSI. We first
examined the flux of pyruvate into other metabolites in estab-
lished LT2/MYC liver tumors. MR anatomic imaging was used
to visualize liver tumors, nontumor tissues, and adjacent normal
structures. Applying a compressed sensing technique, which
allows rapid image acquisition across an entire liver, we per-
formed hyperpolarized 13C 3D spectroscopic imaging with
0.034 cm3 per voxel resolution (Hu et al., 2010). Using this
approach, metabolic imaging of an entire mouse was achieved
in16 s (Figure 3B).We found that 13C-pyruvate could be readily
detected in nontumor tissues such as the kidneys (Figure 3B).
In contrast, 13C-lactate was abundantly detected only in tumor
and not in adjacent tissues (Figure 3B). 13C-alanine was not
appreciably detected in established tumors (Figure 3B). Thus,
consistent with prior studies, tumor tissues have increased flux
of pyruvate to lactate consistent with increased LDH activity.
We next asked whether 13C-pyruvate flux changes during
the course of primary liver tumor development. We imaged
normal liver, pretumor liver tissues, and established tumors
using 13C-pyruvate 3D spectroscopic imaging (Figure 3C). We
found that in pretumor tissues there is a significant increase in
the conversion of 13C-pyruvate to 13C-alanine, which was not
present in either nontumor tissues or established tumors (FiguresFigure 3. Hyperpolarized 13C Metabolic Imaging of Liver Tumor Forma
(A) Diagram showing the conversion of 13C-pyruvate to lactate or alanine.
(B) Color overlay maps from spectroscopic grids show clear differences in meta
(C) Hyperpolarized imaging reveals changes in metabolic profile duringMyc-drive
associated with pretumor liver with modest MYC induction but no apparent phe
masses.
(D) A significant and reproducible pattern of high alanine in pretumor liver compa
(E) Heterogeneous elevation of alanine may correspond to areas of eventual tum
a single animal over the course of disease progression after oncogene activation.
levels. The middle column shows a change in metabolic profile one week later,
highlights heterogeneity in the liver (bright red regions corresponding to highest s
now consisting of a heterogeneous collection of distinct tumor nodules and region
the highest lactate signal intensity. Color intensities were normalized across the
(F) Imaging early tumor regression before and 72 hr after MYC inhibition. A drama
doxy treatment. Spectra for the indicated voxel and corresponding anatomic im
(G) Repeated studies demonstrated a significant increase in lactate during tumor fo
(p < 0.0002). Lactate and alanine are reported as normalized to total carbon (the
Error bars represent the SEM. See also Figure S1.3C and 3D). Thus, conversion to alanine is the earliest metabolic
change we detected and this preceded primary tumor formation.
A sampling of spectra from various liver regions over the course
of disease progression shows that while the average alanine
signal is increased in the pretumor state, there is considerable
heterogeneity between individual voxels in the pretumor liver
(Figure 3E). We found that the regions in pretumor tissue with
the most abundant alanine signal tended to be areas where
tumor nodules would eventually develop. Thus, using this
approach we can detect specific areas with elevated alanine
levels in the pretumor state compared to the rest of the liver.
We next asked how 13C-pyruvate flux is altered when MYC is
inhibited in established tumors. We imaged tumors at baseline
and then again 3 days after the mice were fed a diet containing
doxy to switch off MYC expression (Figures 1A–1C). After
3 days of doxy treatment, liver tumors began to diminish in size,
although substantial tumor mass was still present (Figure 3F)
and was histologically indistinguishable from untreated tumors
(Figure 1A). We examined 13C-pyruvate flux in the tumor tissue
after MYC inhibition. We found a dramatic reversal of the 13C-
pyruvate flux to lactate in early tumor regression (Figure 3F).
Thus, the ratio of 13C-lactate to total carbon rapidly returns to
levels present in nontumor tissue afterMYC inhibition (Figure 3G).
In a series of control experiments, we found that constitutive
expression of the tTA transcription factor in hepatocytes of LT2
transgenic mice compared to wild-type mice did not affect
Lac/tCar or Ala/tCar ratios (Figure S1A). Likewise, doxy treat-
ment of nontumor bearing mice did not alter in vivo metabolic
flux to either alanine or lactate (Figure S1B). This indicates that
the results are not due to underlying toxicity from doxy treatment
or transgene expression. We therefore conclude that inhibiting
MYC in an established liver tumor inhibits glycolysis, resulting
in diminished pyruvate to lactate flux.
We sought to understand the molecular basis for differences
in 13C-pyruvate flux in livers at different stages of Myc-driven
tumorigenesis. We first examined changes in gene expression
of molecules that may impact 13C-pyruvate flux. The MCT1
transporter (SLC16A1) has been proposed to alter uptake of
pyruvate into cells (Harris et al., 2009). We did not detect
appreciable differences in MCT1 expression in tumor tissues
or upon early tumor regression (Figure S1C). Moreover, the
imaging studies were normalized to total 13C signal (tCar) andtion and Regression
bolic profiles between liver tumors and other tissues.
n tumor formation. High pyruvate is detected in normal liver. Elevated alanine is
notypic changes. A substantial increase in lactate is seen in developed tumor
red to controls (p = 0.003) and tumor (p = 0.0002) is observed.
or development. Color overlays generated from spectral grids are shown for
The first column shows a healthy liver that has uniformly low alanine and lactate
with substantially elevated alanine signal now observed. The alanine overlay
ignal intensity). The final column shows the liver 9 weeks afterMyc activation,
s of nontumor. The lactate overlay shows the tumor nodules as the regions with
different time points according to metabolite.
tic decrease in lactate is detected in voxels at similar locations prior and after
aging are shown.
rmation compared to controls (p < 0.0001) and decrease upon early regression
sum of lactate, alanine, and pyruvate).
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Figure 4. Expression of Key Regulators of the Alanine and Glycolysis Biosynthetic Pathways Is Altered at Different Stages of Myc-Driven
Liver Tumor Development
(A) Gpt1 mRNA expression significantly increases during early-stage pretumors and decreases in fully developed liver tumors.
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Metabolic Changes Precede Tumorigenesischanges in MCT1 expression could be accounted for with this
normalization.
Increased Alanine Metabolism Precedes Tumor
Formation
We next examined gene expression changes in enzymes that
regulate alanine and lactate production. The GPT1 (ALT) trans-
aminase is a central regulator of pyruvate to alanine conversion.
We found that GPT1 expression was moderately increased in
pretumor tissues, consistent with the increased 13C-alanine
observed in pretumor tissues (Figure 4A). In contrast, in tumor
tissues or early regression samples GPT1 expression was
dramatically decreased (Figure 4A). This is consistent with the
absence of appreciable Ala / tCar found in imaging studies of es-
tablished tumors.
We next asked whether in addition to Gpt1 other genes in the
alanine biosynthetic pathway are also upregulated in pretumor
tissues. Increased alanine production has been observed in
association with cancer-related cachexia (Heber et al., 1985).
Alanine can also be used for gluconeogenesis, generate cellular
ATP, alter cellular redox potential and generate macromolecule
intermediates useful for anabolism (Berg et al., 2002; Schind-
helm et al., 2006), but to our knowledge this pathway has not
been previously investigated as an early marker of tumor forma-
tion. Using the KEGG pathway database (http://www.genome.
jp/kegg/), we examined 20 genes associated with alanine
metabolism and found that most are upregulated in early-stage
samples compared to normal livers (Figure 4B and Table S2,
p < 0.004). In contrast, most of the alanine-pathway genes are
downregulated in the primary tumors compared to pretumor
samples and remained low upon tumor regression (Figure 4C
and Table S2, p < 0.005). Thus, increased expression of genes
associated with alanine metabolism was associated with
precancerous, early stages of tumor formation, but not in normal
controls or primary and regressing tumors. Besides lactate,
alanine is a major source of cytosolic pyruvate and transamina-
tion enables interconversion of alanine and pyruvate, which may
then be used for gluconeogenesis or anabolic processes. Thus,
our mRNA expression analysis shows that changes in genes
associated with alanine metabolism precede primary tumor
formation and raise the possibility that specific metabolic
markers, such as alanine, may be useful to identify the earliest
stages of tumor formation.
We next examined metabolic changes associated with
primary tumors and early regression. Ldha has been shown to
be the major mediator of tumor-associated glycolysis across
various tumor types (Fantin et al., 2006; Vander Heiden et al.,
2009) by converting pyruvate to lactate. The Ldha gene is also
a direct transcriptional target of Myc in lymphoma and engi-
neered fibroblast cells (Shim et al., 1997). We found that LDHA
expression is similar in normal liver and pretumor tissues with(B) GSEA analysis of alanine-pathway genes reveals upregulation of many gene
Enriched genes are shown.
(C) GSEA analysis of alanine-pathway genes comparing pretumor and tumor samp
in pretumors are shown. Alanine-pathway genes described in the text are indica
(D and E) Ldha mRNA (D) and protein expression (E) show elevated Ldha expres
(F) GSEA analysis of glycolysis genes showing two-way comparisons of glycolytic
Key glycolysis regulators Ldha and Pkm2 are indicated with an asterisk.
Error bars represent the SEM. See also Figure S2 and Table S2.low MYC expression (Figure 4D). In primary tumors, LDHA
expression was increased substantially compared to normal
liver, but expression returned to normal once MYC expression
was inhibited in the early regression tumor samples (Figure 4D).
Quantitative western blotting for LDHA also revealed similar
results (Figure 4E).
While Ldha is a key regulator of glycolysis in tumor tissues
(Dang and Semenza, 1999; Le et al., 2010), we asked whether
multiple glycolytic enzymes are coordinately upregulated in
primary tumors. We determined the expression of 72 genes
associated with glycolysis (http://www.genome.jp/kegg/) and
found that many glycolytic pathway genes, including Ldha
and another key regulator, Pkm2 (Christofk et al., 2008; Vander
Heiden et al., 2009), were enriched in tumor samples compared
to normal liver and pretumor samples (Figure 4F and Table S2). In
contrast, once Myc was switched off, diminished expression of
multiple glycolytic genes including Ldha and Pkm2 (Figure 4F
and Table S2, p < 0.007) was found in early regression samples.
Thus, many, although not all, genes associated with the glycol-
ysis-pathway are dynamically regulated as a consequence of
Myc oncogene signaling as primary tumors form and regress.
Increased ALT and LDH Enzyme Activities Correlate
with the Corresponding Metabolic Imaging Biomarkers
While the changes in Gpt1 and Ldha mRNA abundance
observed in liver tumor formation and regression are consistent
with the observed changes in metabolic imaging, additional
translational or posttranslational modifications could potentially
also alter enzymatic activity that could not be accounted for
entirely by differences in mRNA abundance. We therefore
thought it was critical to determine the enzymatic activity of
these molecules in liver tissues at different stages of tumorigen-
esis. To directly link changes of 13C-pyruvate flux observed
during in vivo imaging to enzyme activity, we collected liver
tissues immediately after imaging. Animals were sacrificed and
tissues were collected for enzymatic activity assays. We found
significantly elevated ALT enzyme activity in pretumor tissues
compared to normal tissues or primary tumors and a correlation
between ALT activity and Alanine/tCar ratio (Figure 5A, R = 0.47,
p = 0.05). Finally, we also found a strong correlation between
LDH Vmax and Lactate / tCar imaging (Figure 5B, R = 0.76,
p < 0.0005).
Expression of Glutamine and Tricarboxylic Acid Cycle
Pathway Genes Changes as Tumors Form and Regress
Several prior studies have identified increased glutamine uptake
and catabolism as an important energy source in cells that over-
express MYC (Dang, 2010; Wise et al., 2008; Yuneva et al.,
2007), but the in vivo importance of this pathway is less clear.
While our current studies with 13C-pyruvate imaging do not allow
us to directly visualize glutamine catabolism, this pathway cans in the pathway in pretumor samples compared to normal liver (p < 0.004).
les shows downregulation of genes in this pathway (p < 0.005). Genes enriched
ted with an asterisk.
sion only in primary tumors.
pathway gene expression at different states of tumor formation and regression.
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AB
Figure 5. ALT and LDH Enzyme Activities Correlate with the
Corresponding Metabolic Imaging Biomarkers
(A) Graph of ALT activity versus alanine/tCar levels across various treatment
conditions demonstrates a correlation between imaging and enzyme activity
(p = 0.05).
(B) Graph of LDH activity versus lactate/tCar levels across various treatment
conditions demonstrates a correlation between imaging and enzyme activity
(p < 0.0005).
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Metabolic Changes Precede Tumorigenesisfeed into alanine production.We therefore examinedwhether the
expression of glutamine-pathway genes (Table S3) is altered in
primary liver tissues as tumors form and regress. We find that
a number of genes in this pathway are increased in the transition
from normal to the pretumor state including glutamate dehydro-
genase (Glud1) and the mitochondrial form of glutamic-oxalo-
acetic transaminase (Got2) (Figure 6A). The glutaminase genes
(Gls and Gls2) were upregulated in only a subset of the pretumor
tissues (Figure 6A). Two glutamine transporters, Slc5a1 and
Slc7a1, are direct transcriptional targets of Myc (Dang, 2010).
We found that Slc7a1 was modestly upregulated in a subset of
pretumor specimens compared to normal liver. With progression
from the pretumor to tumor state we find that Slc7a1, Got2, and
Gls are substantially further upregulated, while Glud1 and Gls2
are markedly downregulated (Figure 6A). Finally, there is a rapid
reversal of these gene expression changes as tumors begin to
regress, with Glud1 and Gls2 increasing and Slc7a1, Gls, and
Got2 being rapidly suppressed (Figure 6A). Our results demon-
strate that gene expression of the glutamine pathway genes
are altered during different stages of tumor formation, and are138 Cell Metabolism 14, 131–142, July 6, 2011 ª2011 Elsevier Inc.consistent with increased glutamine catabolism in Myc-driven
liver tumors and rapid shutoff as tumors begin to regress.
TheMyc oncogene in addition to promoting glycolysis has also
been shown to increase mitochondrial biogenesis (Kim et al.,
2008; Li et al., 2005). Thus it has been proposed that Myc may
provide dual functions by driving both aerobic glycolysis and
oxidative phosphorylation when sufficient oxygen is present
(Dang, 2010). In addition to being converted to alanine or lactate,
pyruvate can also be converted to CO2 and acetyl-CoA, which
can enter the mitochondrial TCA cycle. [1-13C]-pyruvate MRSI
does not allow us to readily visualize the pyruvate that is con-
verted to CO2 with high sensitivity. We therefore examined the
gene expression changes of key regulators of the TCA cycle (Fig-
ure 6B and Table S3). Pyruvate dehydrogenase (Pdha1), the key
regulator of pyruvate entry into the TCA cycle was elevated in the
majority of pretumor tissues, but decreased as they progressed
to tumors (Figure 6B). This is consistentwith an increase in glycol-
ysis in tumor tissues. Interestingly, however, Pdha1 was further
downregulated in the early regression samples compared to
primary tumors. Thus, the inability of Pdha1 to be upregulated
as tumors regress, may explain, at least in part, the rapid exit of
tumor cells from the cell cycle (Figures 1D and 1F) if sufficient
energy production cannot be sustained via the TCA cycle and
subsequent oxidative phosphorylation. We also examined the
expression of Pyruvate dehydrogenase kinase enzymes respon-
sible for inactivating the Pyruvate dehydrogenase complex and
preventing glucose breakdown. The different isoenzymes
(Pdk1–Pdk4) showed deregulated patterns of expression in
each of the stages analyzed (Figure 6B).
DISCUSSION
Increased conversion of glucose into lactate has been observed
in tumor cells in culture; however, the ability to visualize dynamic
changes in glycolysis as a function of oncogene signaling
in vivo has been previously lacking. In this study, we sought
to identify different stages of liver tumor formation and regres-
sion when the driving oncogene c-Myc was temporally regu-
lated. We used hyperpolarized technology to assess metabolic
consequences of Myc-driven liver tumor progression and
regression. We found a strong correlation between LDH activity
and in vivo conversion of pyruvate to lactate. Multiple glycolysis-
pathway genes are upregulated in tumors, and their expression
is rapidly repressed when Myc is switched off (Figures 4 and
7). This MR-based system enables both rapid metabolic assess-
ments and anatomical imaging. Use of hyperpolarized 13C-pyru-
vate MRSI allows for noninvasive visualization of glycolytic
changes within a de novo tumor beyond uptake and the first
enzymatic step.
Interestingly, we found that metabolic changes precede both
tumor formation and regression. The earliest metabolic change
observed was increased alanine in heterogeneous regions of
the pretumor livers. Gpt1 gene expression and ALT enzymatic
activity were elevated in this pretumor state and corresponded
to the elevated Ala/tCar observed (Figure 7). Whether the
elevated Ala/tCar spectra found is unique to livers in which
Myc is the driving oncogene remains unknown. However,
manyMYC target genes potentially connect to increased alanine
production. Multiple genes in the glutamine metabolic pathway
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Figure 6. Expression of Glutamine and TCA Cycle Pathway Genes as Tumors Form and Regress
(A) GSEA analyses of a subset of glutaminemetabolism genes show an increase in expression as tumors develop and decrease in expression as they regress. Key
regulators discussed in the text are indicated with an asterisk.
(B) GSEA analysis of TCA cycle genes. Key regulators Pdha1 and Pdk1 are indicated with an asterisk.
See also Table S3.
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Metabolic Changes Precede Tumorigenesisare regulated by MYC signaling, including glutaminase (Gls) and
the glutamine transporters (Slc5a1 and Slc7a1). GLS acts to
convert glutamine to glutamate. Increased glutamate, along
with pyruvate, is then converted by ALT to alanine and a-ketoglu-
tarate, which in turn may enter the TCA cycle. Thus, elevated
alanine production may be, in part, due to increased glutamine
uptake and catabolism in pretumor tissues to glutamate
(Figure S2).
We also examined other alanine pathway genes whose
expression was altered in the pretumor state and found that
two genes, Aldh2 and Aldh9a1, are known to be direct MYC
targets (http://www.myc-cancer-gene.org/). Both genes are
also substantially upregulated in pretumor tissues compared
to tumors (Figure 4B and Figure S2). Both Aldh2 and Aldh9a1
can participate in the production of beta-alanine from polyamine
degradation. Beta-alanine plus pyruvate can in turn be con-
verted into L-alanine and 3-oxopropanoate by alanine-
glyoxylate aminotransferase 2 (Agxt2). Agxt2 is upregulated inthe pretumor state compared to normal liver and is diminished
in primary tumors (Figures 4B and 4C). Ornithine decarboxylase
(Odc1), a canonical MYC target gene, is rate limiting for poly-
amine synthesis and is upregulated in both pretumor cells and
tumors. Thus, it is possible that MYC may regulate alanine
production at the pretumor state both by upregulating polyamine
synthesis (via direct regulation of Odc1) and by their conversion
into beta-alanine (via direct regulation of Aldh2 and Aldh9a1 in
pretumor tissues). WhyOdc1 expression remains high in tumors,
while Aldh2 and Aldh9a1 expression diminishes is unclear, but it
is well established that MYC may function as both a transcrip-
tional activator and repressor depending on specific cellular
contexts. Thus, there may be multiple Myc-driven pathways
leading to increased alanine production in the pretumor state.
However, it remains to be determined whether other oncogenes
can also upregulate the alanine pathway in pretumor tissues. As
imaging and hyperpolarization techniques continue to improve, it
should be possible to discern with increasing resolution if theCell Metabolism 14, 131–142, July 6, 2011 ª2011 Elsevier Inc. 139
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MYC: OFF
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Figure 7. Changes in Metabolism Correlate with Stages of Myc-Driven Liver Tumor Development and Regression
Schema summarizing the Lactate/tot Carbon, LDHA Vmax, Alanine/tot Carbon, ALT activity levels, andmetabolic gene expression changes in the different stages
of Myc-induced liver tumor progression and regression.
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Metabolic Changes Precede Tumorigenesispretumor tissues with the highest alanine production will ulti-
mately develop into liver tumor nodules.
Finally, in the present study we employed a transgenic liver
tumor model driven by the Myc oncogene. Other oncogenes,
including activated alleles of Ras, Akt, and Pik3ca, or loss of
tumor suppressors (such as p53 and Vhl) have also been shown
to increase glycolysis (Dang, 2009). Thus, the deregulation of
many glycolytic genes is not necessarily directly regulated by
MYC or unique to Myc-driven tumors. Therefore, this approach
should have utility beyond tumors driven by the Myc oncogene.
Metabolic imaging via 13C-pyruvate is a rapid, nonradioactive
approach to visualize glycolysis and alanine pathway changes
in vivo and should provide new metabolic markers of cancer
progression and regression. Clinical studies employing 13C-
pyruvate MRSI imaging technology to visualize tumors in
patients have recently begun. We propose that this approach
may have utility to identify metabolic changes at the earliest
steps of tumor formation and regression.
EXPERIMENTAL PROCEDURES
Mouse Tumor Model
Tet-o-MYC/LAP-tTA (LT2/MYC) double-transgenic mice were obtained by
crossing two transgenic FVB strains (Goga et al., 2007). Under this system,
the Tet transactivator drove MYC expression only in the liver. MYC expression
could be inactivated by doxy to bind and inactivate the Tet transactivator. The
Tet-o-MYC/LAP-tTA mice were weaned on doxy (200 mg/kg) until 4 weeks of
age. Doxy was then removed from the diet to allow induction of expression of
the human c-Myc transgene and tumorigenesis. Mice were monitored weekly
for tumor development by inspection and palpating the abdomen. Tumors
were confirmed by MR anatomic imaging. All animal studies were carried
out under a protocol approved by the University of California, San Francisco
(UCSF) Institutional Animal Care and Use Committee.
Liver Histology and staining
Tissue sections from normal livers of control (LT2) mice, pretumor liver tissue
and primary tumors from established or regressing LT2/MYC tumors were
stained using a standard hematoxylin and eosin (H&E) protocol. Tumor
morphology and tissue histology were examined. c-MYC (Epitomics, 1492)
antibody was used to stain liver tissue sections for MYC. Ready-to-use Ki67
antibody (NeoMarkers) was used for Ki67 staining. TUNEL was performed
with the ApopTag Peroxidase In Situ Apoptosis Detection Kit (Millipore). All
staining was performed on formalin-fixed, paraffin embedded, 5 mm tissue
sections of mouse livers.140 Cell Metabolism 14, 131–142, July 6, 2011 ª2011 Elsevier Inc.Real-Time Quantitative PCR
Gene expression was determined by real-time quantitative PCR. Liver tissues
from four representative samples from each group, normal LT2, early-stage
pretumors, established primary tumors, and regressing tumors were analyzed.
Total RNA from liver tissues was extracted (mirVana mirna isolation kit,
Ambion), followed by Dnase treatment (Turbo DNA-free Dnase Treatment
kit, Ambion) according to the manufacturer’s protocol. Complementary DNA
(cDNA) from 1 mg DNase-treated total RNA was synthesized with the iScript
cDNA synthesis Kit (Bio-Rad). Real-time PCR was carried out with TaqMan
probes (Applied Biosystems) for MYC, LDHA, and GPT1 and SYBR green
(Applied Biosystems) for MCT1 and compared to expression of the house-
keeping gene, GAPDH.
Western Blot Analysis
Antibodies for c-MYC (Epitomics, 1492), AFP (NeoMarkers, RB-365-A1),
and ACTIN (Sigma, A-1978) were purchased and used as indicated by the
respective manufacturers.
mRNA Microarrays
Total RNA from LT2 controls (n = 3), pretumor early-stage samples (n = 4),
established LT2/MYC liver tumors (n = 4), and early regression tumor samples
(n = 4) was extracted (mirVana mirna isolation kit, Ambion). RNA quality was
assessed with the Nanodrop ND-8000 (Nanodrop Technologies) and a Pico
Chip on an Agilent 2100 Bioanalyzer (Agilent Technologies) and run on Agilent
mouse whole genome 4x44K Ink-jet arrays. Sample preparation, labeling, and
array hybridizations were performed according to standard protocols from
UCSF Shared Microarray Core Facilities and Agilent Technologies (http://
www.arrays.ucsf.edu/ and http://www.agilent.com/). RNA was amplified
with the Sigma whole transcriptome amplification kit (Sigma-Aldrich), and
subsequent Cy3-CTP labeling was performed with NimbleGen one-color
labeling kits (Roche-NimbleGen). The labeled DNA was assessed with Nano-
drop 8000, and equal amounts of Cy3 labeled target were hybridized to Agilent
mouse whole genome 4x44K Ink-jet arrays. Hybridizations were performed for
14 hr, according to the manufacturer’s protocol (Agilent). Arrays were scanned
with the Agilent microarray scanner, and raw signal intensities were extracted
with Feature Extraction v10.1 software.
Primary normalization and data extraction were done by theMicroarray Core
Facility. In brief, raw log-intensities were normalized via the quantile normaliza-
tion method (Bolstad et al., 2003). No background subtraction was performed,
and the median feature pixel intensity was used as the raw signal before
normalization. A one-way ANOVA model was used and specific contrasts
were formulated to examine pair-wise comparisons of interest.
Microarray Data Analyses
Effect of Inactivation of the Myc Oncogene in Liver Tumor Models
Subsets of MYC target genes belonging to different pathways frequently
reported to be targeted by MYC were selected from the MYC cancer gene
Cell Metabolism
Metabolic Changes Precede Tumorigenesisdatabase (http://www.myc-cancer-gene.org/ and Table S1). Genes selected
are associated with various pathways, including cell cycle, apoptosis, DNA
repair, chromatin remodeling, and glycolysis, alanine, and glutamine meta-
bolic pathways. Hierarchical clustering was performed, and the four study
groups (LT2 controls, pretumor early-stage mice, established LT2/MYC liver
tumor, and regressing LT2/MYC liver tumor mice) were compared.
Comparison of Specific Metabolic Pathways in Developing
and Regressing Myc-Driven Liver Tumors
Expression of genes associated with energy and anabolic metabolic pathways
such as glycolysis and alanine metabolism was compared in the four study
groups via GSEA (Subramanian et al., 2005). Gene lists for the glycolysis
and alanine metabolic pathways were obtained from the KEGG database
(http://www.genome.jp/kegg/pathway.html).
GSEA was used to determine the significance of differentially expressed
MYC target genes and specific metabolic pathways in normal livers, early-
stage pretumors, primary developed tumors, and tumors in early regression.
Predefined gene lists including 120MYC targets genes frommultiple pathways
regulated by MYC, 78 glycolysis genes, and 20 alanine metabolism genes
were used in GSEA. The gene set permutation was used instead of phenotype
in order to avoid the potential problem of a small sample size.
Dynamic Nuclear Polarization and Injection of Hyperpolarized
Pyruvate
The dynamic nuclear polarization and data acquisition protocols are described
previously (Hu et al., 2010). An aliquot of 24 ml [1-13C] pyruvic acid with 15 mM
OX63 trityl radical and 1.5 mM Dotarem gadolinium were polarized for 1 hr in
a 3.35T magnetic field at 1.35 Kelvin with a Hypersense DNP polarizer (Oxford
Instruments, Abingdon, UK). The power of the microwave irradiation was 20
mW. The solvent used to dissolve the frozen solid state sample was an
aqueous mixture containing 40 mM Tris, 80 mMNaOH, and 0.3 mMNa2EDTA.
The resulting pyruvate concentration was 80 mM, with a pH of7.5 and polar-
izations greater than 30% upon dissolution. A 350 ml volume of the dissolved
pyruvate, followed by a 150 ml saline flush, was injected into mice through
a tail vein catheter. A compressed sensing pulse sequence with 0.034 cm3
voxel resolution was used to acquire 3D MRSI data. The uptake of 13C-pyru-
vate and conversion to 13C-lactate and 13C-alanine were monitored with 3D
spectroscopic imaging as described below. Mice were anesthetized with iso-
flurane and kept warm with a circulating-water heating pad.
Magnetic Resonance Imaging and Spectroscopic Imaging
All experiments were performed on a General Electric 3T (Waukesha, WI) MRI
scanner equipped with 40 mT/m, 150 mT/m/ms gradients, and a broadband
RF amplifier. The RF coil was a custom built, dual-tuned 1H/13C transmit/
receive design used previously (Albers et al., 2008; Hu et al., 2010). T2-
weighted proton fast spin-echo (FSE) images were acquired and used as the
anatomical reference on which 13C spectra were overlaid and coregistered.
The axial FSE imaging parameters were as follows: FOV = 8 cm, 192 3 192
matrix, 2 mm slice thickness, and NEX = 6. Carbon-13 hyperpolarized spectra
were acquired as a volumetric grid with a compressed sensing 3D-MRSI
sequence (Hu et al., 2010). Acquisition parameters were as follows: variable
flip angle, TE = 140 ms, TR = 215 ms, 163 16 in-plane phase encodes, center
out phase encode order, 2.5 mm 3 2.5 mm in-plane resolution, flyback
readout in z with 16 points and 5.4 mm resolution, 581 Hz spectral bandwidth,
and 9.8 Hz spectral resolution. The 13C 3D-MRSI scan was started 30 s after
injection of the hyperpolarized 13C-pyruvate and lasted 16 s. To quantify
metabolism in the 13C spectra, the areas under the 13C-lactate, 13C-pyru-
vate-hydrate, 13C-alanine, and 13C-pyruvate peaks (total carbon-13 defined
as the sum of all four) in magnitude spectra were calculated. The ratios lactate
area to total carbon area (Lactate/tCar) and alanine area to total carbon
(Alanine/tCar) were computed for each voxel and then averaged over all voxels
of interest for each mouse to derive the final lac/tCar and ala/tCar values for
statistical analysis.
Ex Vivo LDH Activity
Total LDH activity wasmeasured through anNADH-linked spectrophotometric
method by observing the decrease in absorbance of NADH at 339 nm after
addition of varying concentrations of pyruvate. Around 0.2 g of frozen tissue
was thawed in lysis buffer containing 50 mM Tris (pH 8.2), 2 mM DTT, 2 mMEDTA, and 1% Triton x-100. The tissue was homogenized and centrifuged
for 1 min at 7000 rpm at 4C. The supernatant was removed and diluted
appropriately so that the reduction of NADH was linear over the first ten
minutes of the assay. In microplate wells, 3 ml cell lysate was mixed with
147 ml reaction buffer containing varying concentrations of pyruvate, 80 mM
Tris (pH 7.2), 200 mM NaCl, and 200 mM NADH that was heated to 30C.
The assay was conducted immediately by monitoring the decrease in NADH
absorbance, at 339 nm, for 10 min with an Infinite M200 spectrophotometer
(Tecan). Each pyruvate concentration was assayed in triplicate. The reaction
rate was normalized to total protein concentration (Quick Start Bradford
Protein Assay, Bio-Rad). Each sample was assayed in triplicates, at 595 nm,
after incubating at room temperature for at least 5 min. The absorbance of
the sample was then recorded, and protein concentration calculated with
a gamma-globulin standard curve. Once the sample’s protein concentration
had been acquired, it was used to calculate LDH reaction rate for the varying
pyruvate concentrations. The LDH reaction rate, measured in mM NADH/min/
[protein], was plotted against pyruvate concentrations according to Michaelis-
Menten kinetics. The maximum velocity (Vmax) and Km values were then
calculated with the Lineweaver-Burk plot.
Ex Vivo ALT Activity
ALT activity was measured with a commercially available enzymatic assay kit
(MaxDiscovery). A coupled reaction scheme was used in which the first step
was alanine and alpha-ketoglutarate conversion to glutamate and pyruvate
by ALT. Pyruvate and NADH were then converted to lactate and NAD+ by
lactate dehydrogenase, and activity was detected spectrophotometrically by
measurement of absorbance at 339 nm.
Statistical Analysis
All statistical analysis was performed with the JMP software package. For the
13CMRSI statistical analysis, experimental data were divided into four groups:
normal liver (Tet transactivator control mice [n = 5]), pretumor (Tet-o-MYC/
LAP-tTA mice with Myc on >30 days and no tumor on anatomic imaging
[n = 5]), tumor (Tet-o-MYC/LAP-tTA mice with Myc on and tumor confirmed
by anatomic imaging [n = 8]), and early regression (Tet-o-MYC/LAP-tTA tumor
mice in whichMyc has been off for 72 hr [n = 4]). For animals with repeat acqui-
sitions, e.g., two scans in a row to determine reproducibility, the average of the
measurements was used. Normal liver, pretumor, tumor, and early regression
groups were compared with Tukey’s test after a one-way ANOVA was per-
formed. Note that four mice in the Tumor group had a baseline 13C MRSI
imaging exam and a repeat 72 hr after MYC was kept on. The four mice in
the early regression group received a 13C MRSI baseline study and then
a follow-up 72 hr after inhibiting MYC. Thus, there are eight total animals in
the tumor group (in which a baseline tumor 13C MRSI was performed) and
four in the early regression group. Consequently, tissues were collected
from four tumor group mice and four early regression group mice. For the
expression comparisons, a Student’s t test was used, and for enzyme activity
correlations, the Pearson product-moment was computed, after which the
Student’s t test was used to test for statistical significance.
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